TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Hits Estimates

TriSalus Life Sciences (NASDAQ:TLSI) posted its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35), Zacks reports. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Stock Down 1.3 %

TLSI stock traded down $0.07 during mid-day trading on Thursday, hitting $5.51. The company had a trading volume of 18,140 shares, compared to its average volume of 42,757. The company has a 50-day moving average price of $5.38 and a 200 day moving average price of $4.73. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42. The company has a market capitalization of $168.02 million, a price-to-earnings ratio of -2.21 and a beta of 0.48.

Wall Street Analysts Forecast Growth

TLSI has been the topic of several analyst reports. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target on the stock. Roth Mkm restated a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Lake Street Capital began coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price for the company. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Buy” and an average price target of $11.56.

Insider Activity

In other TriSalus Life Sciences news, CFO James Emmett Young acquired 24,000 shares of the stock in a transaction on Monday, January 27th. The stock was acquired at an average price of $5.40 per share, for a total transaction of $129,600.00. Following the completion of the transaction, the chief financial officer now directly owns 24,000 shares of the company’s stock, valued at $129,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mary T. Szela bought 4,826 shares of TriSalus Life Sciences stock in a transaction dated Monday, January 27th. The stock was acquired at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the acquisition, the chief executive officer now owns 429,503 shares in the company, valued at approximately $2,327,906.26. The trade was a 1.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 54,856 shares of company stock worth $294,608 over the last 90 days. Corporate insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.